Portside Wealth Group
LGND icon

Portside Wealth Group’s Ligand Pharmaceuticals LGND Stock Holding History

Portside Wealth Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.57M Buy
5,034
+224
+5% +$66.2K 0.17% 134
2026
Q2 		$1.52M Buy
4,810
+1,793
+59% +$422K 0.18% 134
2026
Q1 		$602K Buy
3,017
+184
+6% +$36.4K 0.08% 226
2025
Q4 		$536K Sell
2,833
-1,385
-33% -$266K 0.07% 242
2025
Q3 		$747K Buy
4,218
+725
+21% +$108K 0.1% 203
2025
Q2 		$397K Sell
3,493
-82
-2% -$8.76K 0.06% 283
2025
Q1 		$376K Buy
3,575
+112
+3% +$12.7K 0.06% 279
2024
Q4 		$371K Buy
3,463
+363
+12% +$41K 0.06% 275
2024
Q3 		$310K Buy
3,100
+378
+14% +$38.1K 0.05% 302
2024
Q2 		$229K Buy
+2,722
New +$217K 0.04% 318

Other funds holding LGND

Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Portside Wealth Group's LGND Position: Q3 2026 in Review

Portside Wealth Group increased its Ligand Pharmaceuticals (LGND) stake by 4.7% in Q3 2026, buying an estimated $66.2K and bringing the position to 5,034 shares worth $1.57M. The position accounts for 0.17% of the portfolio, ranked #134.

Portside Wealth Group first reported a position in LGND in Q2 2024 and has held it in 10 quarters since. 296 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Portside Wealth Group held 5,034 shares of Ligand Pharmaceuticals worth $1.57M as of Q3 2026.
  • Portside Wealth Group bought 224 Ligand Pharmaceuticals shares in Q3 2026, an estimated $66.2K.
  • Ligand Pharmaceuticals made up 0.17% of Portside Wealth Group's portfolio in Q3 2026, its #134 holding.
  • Portside Wealth Group first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
  • 296 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Portside Wealth Group's 13F filing for Q3 2026, filed 20 Oct 2026.